The lack of CREB can be compensated by other β‐catenin co‐activators, which explains why ICG001 failed to reduce liver fibrosis in patients with cirrhosis.[58] Direct effect on β‐catenin expression or metabolism may represent a better strategy for treating fibrosis, as in the case of XAV939. Here, CREB1 is linked to Hepatic fibrosis.